While not a mind-blowing move, it is good to see that the Viemed Healthcare, Inc. (NASDAQ:VMD) share price has gained 10% in the last three months. But that is minimal compensation for the share price under-performance over the last year. In fact the stock is down 11% in the last year, well below the market return.

Now let’s have a look at the company’s fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

Even though the Viemed Healthcare share price is down over the year, its EPS actually improved. It’s quite possible that growth expectations may have been unreasonable in the past.

The divergence between the EPS and the share price is quite notable, during the year. So it’s well worth checking out some other metrics, too.

Viemed Healthcare managed to grow revenue over the last year, which is usually a real positive. Since the fundamental metrics don’t readily explain the share price drop, there might be an opportunity if the market has overreacted.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

We know that Viemed Healthcare has improved its bottom line lately, but what does the future have in store? This free report showing analyst forecasts should help you form a view on Viemed Healthcare

While the broader market gained around 17% in the last year, Viemed Healthcare shareholders lost 11%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year’s performance may indicate unresolved challenges, given that it was worse than the annualised loss of 1.2% over the last half decade. We realise that Baron Rothschild has said investors should “buy when there is blood on the streets”, but we caution that investors should first be sure they are buying a high quality business. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.